Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Medizone International, Inc. (MZEI.OB) Announces Successful Completion of Testing of AsepticSure

Yesterday, Medizone International Inc., a research and development company, announced the successful completion of the first round of beta testing for its AsepticSure system at Hotel Dieu Hospital in Ontario, Canada, which is affiliated with Queen’s University.

The system will be used to decontaminate and sterilize surgical suites, emergency rooms, intensive care units, patient rooms and schools, among other areas prone to contamination. A variant is being developed for the government to be used in bio-terrorism countermeasures. Additional variants will be developed for commercial use; for example, sports facilities and food processing plants.

Dr. Michael E. Shannon stated, “We are absolutely delighted with the results. Pre-inoculated stainless steel test discs as well as carpet swatches typically found in many health care facilities were placed in selected locations to assess for antimicrobial effects. Not only were 100% of the MRSA and C. difficile spores eliminated from the stainless steel discs (7.1 logs bacterial kill for MRSA and 6.2 log bacterial kill for C difficile spores), the pathogens were also completely eliminated from all contaminated carpet samples, something unachievable with any other technology we are aware of. Thus, the system performed to our highest expectations. The AsepticSure system has proven to be able to achieve a very high level of microbial kill to the sterilization standard of > 6 log (99.9999%) in the laboratory setting and now in a hospital setting.”

Dr. David Pichora, a leading orthopedic and hand surgeon, and the hospital’s Chief Executive Officer, added, “I am pleased that Hotel Dieu Hospital has been able to participate in what appears to be a promising breakthrough in addressing the global challenge of reducing hospital acquired infections. The results of the AsepticSure sterilization technology tests are encouraging. Technology that could help hospitals improve patient safety, reduce infection rates and reduce costs is exciting, indeed. We are pleased to be participating in this safety initiative and we look forward to continued participation.”

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net



Disclosure: no positions